Amlx forecast

**Amylyx Pharmaceuticals Inc. (AMLX) is forecasted to have a net loss of $118.79 million, a total revenue of $88.64 million, and a diluted EPS of -$1.75 as of Q1 2024.** |stock code|stock name|Total Revenue[20240331]|Net Income[20240331]|Diluted EPS[20240331]| |---|---|---|---|---| |AMLX.O|Amylyx Pharmaceuticals|$88.64 million|$-118.79 million|$-1.75| 1. **Financial Performance**: The company has reported a net loss of $118.79 million, which is a significant amount compared to the previous quarter's net loss of $6.60 million. This indicates that the company's financial performance is deteriorating. The diluted EPS is -$1.75, reflecting a deep loss per share. 2. **Revenue Trends**: The total revenue for the quarter was $88.64 million, which is a decrease from the previous quarter's revenue of $102.7 million. This suggests that the company's revenue is not growing significantly. 3. **Growth Rates**: The net income year-on-year growth rate is -1.09%, and the total revenue year-on-year growth rate is -16.82%. These negative growth rates indicate that the company is experiencing a decline in financial performance. 4. **Analyst Sentiments**: The average analyst price target is $6.2, with a high forecast of $8.00 and a low forecast of $3.00. This suggests that analysts have a wide range of expectations for the stock's future performance. 5. **Stock Performance**: The 5-day moving average is $2.68, and the 10-day moving average is $2.92. The stock has experienced a significant decline, with a 36.65% interval percentage change. In conclusion, Amylyx Pharmaceuticals is forecasted to continue its current financial trajectory, with a net loss and negative growth rates in revenue and diluted EPS. Analysts have a wide range of expectations for the stock's future performance, with some predicting a potential upside. Investors should consider the company's financial performance and the specific risks and opportunities within the pharmaceutical industry when evaluating the stock's potential.